Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
12:27pm, Wednesday, 28'th Jan 2026
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock
05:22am, Saturday, 24'th Jan 2026
Amicus Therapeutics, Inc. (NASDAQ: FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of the company's stock in a transaction dated Tuesday, January 20th. The shares were sold at an avera
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
07:37am, Friday, 23'rd Jan 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per s
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks w
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock?
12:07pm, Friday, 16'th Jan 2026
Amicus stock soars 135.8% in six months as demand for marketed products grows. The company is set to be acquired by BioMarin for $4.8 billion.
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit
06:47am, Thursday, 15'th Jan 2026
Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum.
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
12:15pm, Tuesday, 06'th Jan 2026
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights
10:19am, Tuesday, 30'th Dec 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights
06:45pm, Tuesday, 23'rd Dec 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
BALA CYNWYD, Pa. , Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
What's Going On With BioMarin Stock On Tuesday?
01:05pm, Tuesday, 23'rd Dec 2025
On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion.
BioMarin: Amicus Buyout Sparks My Enthusiasm
03:15pm, Monday, 22'nd Dec 2025
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example,
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the "Santa Claus"
